Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $20.87 to $23.83
• 50-Day Range: $4.25 to $27.58
• 52-Week Range: $3.81 to $37.50
• Volume: 113,591 shs
• Average Volume: 177,873 shs
• Market Capitalization: $27.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Hold

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 461st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -16.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -16.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyra Therapeutics has a P/B Ratio of 15.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.09% of the float of Lyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 94.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.09% of the float of Lyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 94.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.40

News Sentiment

Lyra Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Lyra Therapeutics this week, compared to 0 articles on an average week.

Search Interest

22 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 214% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.25% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYRA Stock Analysis - Frequently Asked Questions

How have LYRA shares performed this year?

Lyra Therapeutics' stock was trading at $10.32 on January 1st, 2025. Since then, LYRA stock has increased by 135.3% and is now trading at $24.28.
View the best growth stocks for 2025 here.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($6.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.50) by $1.50. The firm earned $0.18 million during the quarter, compared to analyst estimates of $0.16 million. Lyra Therapeutics had a negative net margin of 6,635.76% and a negative trailing twelve-month return on equity of 125.07%.

When did Lyra Therapeutics' stock split?

Lyra Therapeutics's stock reverse split on Wednesday, May 28th 2025. A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

Who are Lyra Therapeutics' major shareholders?

Top institutional investors of Lyra Therapeutics include Goldman Sachs Group Inc. (0.56%). Insiders that own company stock include Perceptive Advisors Llc, Nbvm Gp, Llc, Harlan Waksal and C Ann Merrifield.
View institutional ownership trends.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/09/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $100.00
• High Stock Price Target: $100.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: +311.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($60.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.68 million
• Net Margins: -6,635.76%
• Pretax Margin: -6,632.36%
• Return on Equity: -125.07%
• Return on Assets: -59.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.64
• Quick Ratio: 3.64

Sales & Book Value

• Annual Sales: $1.19 million
• Price / Sales: 27.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.56 per share
• Price / Book: 15.56

Miscellaneous

• Outstanding Shares: 1,325,000
• Free Float: 62,388,000
• Market Cap: $32.17 million
• Optionable: Optionable
• Beta: -0.01